Related Experiment Videos
[Management of elevated blood pressure and hypertension : Focus on risk reduction]
Raphael S Schmieder1, Heribert Schunkert2,3
1Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München (DHM), Universitätsklinikum der Technischen Universität München, München, Deutschland. schmieder@dhm.mhn.de.
Insights
The 2024 European Society of Cardiology (ESC) guidelines introduce
Area of Science:
- Cardiology and Hypertension Management
Background:
- Blood pressure is a continuous cardiovascular risk factor.
- New guidelines emphasize early prevention for elevated blood pressure.
- Comorbid conditions necessitate tailored hypertension management.
Purpose of the Study:
- To outline the 2024 European Society of Cardiology (ESC) hypertension guidelines.
- To define management strategies for elevated blood pressure and hypertension.
- To highlight treatment targets and options for resistant hypertension.
Main Methods:
- Introduction of 'elevated blood pressure' category (120-139/70-89 mmHg).
- Emphasis on lifestyle modifications for all affected individuals.
- Pharmacotherapy recommendations based on blood pressure levels and cardiovascular risk.
Main Results:
- Antihypertensive treatment may be initiated below the traditional hypertensive range.
- Pharmacotherapy advised if blood pressure remains >130/80 mmHg with comorbidities or high risk.
- Concurrent lifestyle measures and dual therapy recommended at ≥140/90 mmHg.
Conclusions:
- Target systolic blood pressure is 120-129 mmHg, with exceptions for frail or elderly patients.
- Spironolactone is recommended for resistant hypertension.
- Renal denervation is an interventional option for resistant hypertension.
Abstract:
The 2024 hypertension guidelines from the European Society of Cardiology (ESC) introduce the category of 'elevated blood pressure' (120-139/70-89 mm Hg) and emphasise the importance of early prevention in individuals with such blood pressure levels and comorbid conditions. As blood pressure is recognised as a continuous risk factor, early initiation of antihypertensive treatment may be recommended even below the hypertensive range, depending on overall cardiovascular risk. All affected individuals should adopt a healthy lifestyle: regular exercise, balanced diet, reduced alcohol and salt intake, weight loss, and smoking cessation. If blood pressure remains > 130/80 mm Hg after three months and the patient has cardiovascular disease, heart failure, or a moderate to high risk, pharmacotherapy is advised. At ≥ 140/90 mm Hg, lifestyle measures and low-dose dual combination therapy should be initiated concurrently. The target systolic blood pressure is 120-129 mm Hg, with exceptions for individuals with frailty or those aged > 85 years. For resistant hypertension, spironolactone is the recommended pharmacological therapy, while renal denervation is listed as an interventional option.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Atherosclerosis III: Management
Factors affecting Blood pressure
Physiological Factors:
Hypertension I: Introduction